Related Experiment Videos
[Clinical trial of parenteral trimethoprim-sulfamethoxazole]
Abstract:
The combination of trimethoprim-sulfamethoxazole has been used successfully in various infections. However the use of the combination was limited, due to the lack of a parenteral form of the drug. In this study a parenteral (i.m.) form of trimethoprim-sulfamethoxazole was given to 35 patients with various infections due to susceptible bacteria to the drug. Twenty-four patients had urinary tract infections, and 7 had various infections with gram negative organisms, and 4 had staphylococcal infections. In patients with urinary tract infection the cure rate was 62.5%. Twenty five per cent of the patients had persistent infection after treatment, and 12,5% had superinfection. The overall cure rate was 71,4% in 35 patients. No side effect was observed.
Insights
A new injectable form of trimethoprim-sulfamethoxazole offers effective treatment for bacterial infections, including urinary tract infections, with no observed side effects in patients. This advance expands therapeutic options for susceptible bacterial infections.
Area of Science:
- Pharmacology
- Infectious Diseases
- Bacteriology
Background:
- Trimethoprim-sulfamethoxazole is a widely used antibiotic combination.
- Limited availability of parenteral formulations restricted its clinical application.
- Development of an injectable form addresses this therapeutic gap.
Purpose of the Study:
- To evaluate the efficacy and safety of an intramuscular (i.m.) formulation of trimethoprim-sulfamethoxazole.
- To assess treatment outcomes in patients with various bacterial infections.
Main Methods:
- A cohort of 35 patients with susceptible bacterial infections received intramuscular trimethoprim-sulfamethoxazole.
- Patient populations included those with urinary tract infections (n=24), gram-negative organism infections (n=7), and staphylococcal infections (n=4).
Main Results:
- An overall cure rate of 71.4% was achieved across all treated patients.
- In patients with urinary tract infections, the cure rate was 62.5%.
- No adverse side effects were reported during the study period.
Conclusions:
- Intramuscular trimethoprim-sulfamethoxazole is an effective and safe treatment option for various bacterial infections.
- The parenteral formulation expands treatment possibilities where oral administration is not feasible.
- Further research may explore broader applications and comparative effectiveness.